FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750729412> ?p ?o ?g. }

• W2750729412 endingPage "4250" @default.
• W2750729412 startingPage "4239" @default.
• W2750729412 abstract "Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic and pharmacodynamic parameters, and assess antitumor activity.Omaveloxolone was administered orally once daily continuously in a 28-day cycle for patients with stage 4 relapsed/refractory melanoma or non-small cell lung cancer. An accelerated titration design was employed until a grade 2-related adverse event (AE) occurred. A standard 3+3 dose escalation was employed. Single-dose and steady-state plasma pharmacokinetics of the drug were characterized. Downstream Nrf2 activation was assessed in peripheral blood mononuclear cells by quantification of target gene mRNA expression.Omaveloxolone was tested at four dose levels up to 15 mg given orally once daily. No dose-limiting toxicities were detected, and the maximum tolerated dose was not determined. All drug-related AEs were either grade 1 or 2 in severity, and none required clinical action. The most common drug-related AEs were elevated alkaline phosphatase (18%) and anemia (18%). No drug interruptions or reductions were required. Omaveloxolone was rapidly absorbed and exhibited proportional increases in exposure across dose levels. With some exceptions, an overall trend toward time-dependent and dose-dependent activation of Nrf2 antioxidant genes was observed. No confirmed radiologic responses were seen, although one lung cancer subject did have stable disease exceeding 1 year.Omaveloxolone has favorable tolerability at biologically active doses, although this trial had a small sample size which limits definitive conclusions. These findings support further investigation of omaveloxolone in cancer." @default.
• W2750729412 created "2017-09-15" @default.
• W2750729412 creator A5007121755 @default.
• W2750729412 creator A5022912407 @default.
• W2750729412 creator A5026477179 @default.
• W2750729412 creator A5026672076 @default.
• W2750729412 creator A5041091140 @default.
• W2750729412 creator A5044766130 @default.
• W2750729412 creator A5046273815 @default.
• W2750729412 creator A5047177507 @default.
• W2750729412 creator A5049168967 @default.
• W2750729412 creator A5061834802 @default.
• W2750729412 creator A5062655853 @default.
• W2750729412 creator A5064494204 @default.
• W2750729412 creator A5064826649 @default.
• W2750729412 creator A5073189087 @default.
• W2750729412 creator A5088903572 @default.
• W2750729412 date "2017-08-01" @default.
• W2750729412 modified "2023-09-24" @default.
• W2750729412 title "Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors" @default.
• W2750729412 cites W1567187437 @default.
• W2750729412 cites W1936755024 @default.
• W2750729412 cites W1971670881 @default.
• W2750729412 cites W1989035683 @default.
• W2750729412 cites W2013948993 @default.
• W2750729412 cites W2019607817 @default.
• W2750729412 cites W2028166635 @default.
• W2750729412 cites W2028578736 @default.
• W2750729412 cites W2043991982 @default.
• W2750729412 cites W2046768931 @default.
• W2750729412 cites W2053655027 @default.
• W2750729412 cites W2078495613 @default.
• W2750729412 cites W2083672871 @default.
• W2750729412 cites W2087633043 @default.
• W2750729412 cites W2087928294 @default.
• W2750729412 cites W2093534329 @default.
• W2750729412 cites W2097637096 @default.
• W2750729412 cites W2099852670 @default.
• W2750729412 cites W2108012025 @default.
• W2750729412 cites W2110639241 @default.
• W2750729412 cites W2120742807 @default.
• W2750729412 cites W2128976658 @default.
• W2750729412 cites W2149008396 @default.
• W2750729412 cites W2158131507 @default.
• W2750729412 cites W2160358010 @default.
• W2750729412 cites W2217763015 @default.
• W2750729412 cites W2255208761 @default.
• W2750729412 cites W2267367070 @default.
• W2750729412 cites W2294546373 @default.
• W2750729412 cites W2411733041 @default.
• W2750729412 cites W2496925402 @default.
• W2750729412 doi "https://doi.org/10.2147/ott.s136992" @default.
• W2750729412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5587199" @default.
• W2750729412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28919776" @default.
• W2750729412 hasPublicationYear "2017" @default.
• W2750729412 type Work @default.
• W2750729412 sameAs 2750729412 @default.
• W2750729412 citedByCount "34" @default.
• W2750729412 countsByYear W27507294122018 @default.
• W2750729412 countsByYear W27507294122019 @default.
• W2750729412 countsByYear W27507294122020 @default.
• W2750729412 countsByYear W27507294122021 @default.
• W2750729412 countsByYear W27507294122022 @default.
• W2750729412 crossrefType "journal-article" @default.
• W2750729412 hasAuthorship W2750729412A5007121755 @default.
• W2750729412 hasAuthorship W2750729412A5022912407 @default.
• W2750729412 hasAuthorship W2750729412A5026477179 @default.
• W2750729412 hasAuthorship W2750729412A5026672076 @default.
• W2750729412 hasAuthorship W2750729412A5041091140 @default.
• W2750729412 hasAuthorship W2750729412A5044766130 @default.
• W2750729412 hasAuthorship W2750729412A5046273815 @default.
• W2750729412 hasAuthorship W2750729412A5047177507 @default.
• W2750729412 hasAuthorship W2750729412A5049168967 @default.
• W2750729412 hasAuthorship W2750729412A5061834802 @default.
• W2750729412 hasAuthorship W2750729412A5062655853 @default.
• W2750729412 hasAuthorship W2750729412A5064494204 @default.
• W2750729412 hasAuthorship W2750729412A5064826649 @default.
• W2750729412 hasAuthorship W2750729412A5073189087 @default.
• W2750729412 hasAuthorship W2750729412A5088903572 @default.
• W2750729412 hasBestOaLocation W27507294121 @default.
• W2750729412 hasConcept C111113717 @default.
• W2750729412 hasConcept C112705442 @default.
• W2750729412 hasConcept C126322002 @default.
• W2750729412 hasConcept C197934379 @default.
• W2750729412 hasConcept C2776256026 @default.
• W2750729412 hasConcept C2778375690 @default.
• W2750729412 hasConcept C2780035454 @default.
• W2750729412 hasConcept C71924100 @default.
• W2750729412 hasConcept C98274493 @default.
• W2750729412 hasConceptScore W2750729412C111113717 @default.
• W2750729412 hasConceptScore W2750729412C112705442 @default.
• W2750729412 hasConceptScore W2750729412C126322002 @default.
• W2750729412 hasConceptScore W2750729412C197934379 @default.
• W2750729412 hasConceptScore W2750729412C2776256026 @default.
• W2750729412 hasConceptScore W2750729412C2778375690 @default.
• W2750729412 hasConceptScore W2750729412C2780035454 @default.
• W2750729412 hasConceptScore W2750729412C71924100 @default.
• W2750729412 hasConceptScore W2750729412C98274493 @default.

• next